Novavax Inc. develops and partners vaccine technologies built around Matrix-M adjuvant technology and protein-based nanoparticles. Company news centers on marketed vaccine products, including Nuvaxovid and R21/Matrix-M, licensing and material-transfer agreements with pharmaceutical companies, and research programs for infectious disease and other vaccine applications.
Recurring updates also cover quarterly financial results, revenue from product sales and partner arrangements, R&D prioritization such as its C. difficile vaccine candidate, operating-efficiency initiatives, investor conference participation, and leadership changes within research and development.
On September 29, 2021, Novavax (Nasdaq: NVAX) announced its participation in the upcoming 2021 Maryland Life Sciences Bio Innovation Conference. The company will discuss its recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, during a panel titled Health Equity and Vaccine Confidence. This panel is scheduled for October 4, 2021, from 1:00 to 1:50 p.m. EDT. Notable speakers include Lisa M. Dunkle, M.D. from Novavax, alongside other experts from the Department of Defense and the University of Maryland.
On September 23, 2021, Novavax hosted HM King Carl XVI Gustaf and HM Queen Silvia at its Uppsala facility to discuss the progress of NVX-CoV2373, its COVID-19 vaccine candidate. The visit highlighted Novavax's commitment to global vaccination efforts, with a focus on its patented Matrix-M™ adjuvant, enhancing immune response. NVX-CoV2373 has shown high efficacy in Phase 3 trials, including 100% efficacy against severe disease. Novavax is also advancing its NanoFlu™ vaccine and is committed to addressing urgent global health needs.
Novavax, Inc. (Nasdaq: NVAX) announced the publication of complete results from its pivotal Phase 3 trial of NanoFlu™, a recombinant quadrivalent seasonal influenza vaccine, in The Lancet Infectious Diseases. The trial demonstrated NanoFlu's enhanced immunogenicity and safety compared to a leading influenza vaccine in older adults. The vaccine achieved all primary endpoints, showing significantly improved immune responses, including a 22-66% increase in antibody responses. The findings support NanoFlu's potential efficacy, particularly amid ongoing evaluations for a combination COVID-19-influenza vaccine.
Novavax, Inc. (Nasdaq: NVAX) has submitted a regulatory application for emergency use listing of its recombinant nanoparticle protein-based COVID-19 vaccine to the World Health Organization (WHO) in collaboration with the Serum Institute of India. This submission aims to facilitate equitable vaccine distribution globally, particularly through the COVAX Facility. The vaccine demonstrated high efficacy in pivotal Phase 3 trials, achieving 100% protection against severe disease and 90.4% overall efficacy. The NVX-CoV2373 vaccine is designed to be easily stored and administered, reinforcing Novavax's commitment to combating the pandemic.
Novavax, Inc. (Nasdaq: NVAX) announced its participation in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 29, 2021, from 8:40 – 9:10 a.m. EDT. The discussion will feature the company's COVID-19 vaccine candidate, NVX-CoV2373. Key participants include Gregory M. Glenn, M.D., and John J. Trizzino. A replay of the session will be available on the company's website for 90 days. Novavax is advancing its developing vaccines, including NanoFlu™, which is set for regulatory submission.
Novavax (Nasdaq: NVAX) announced that John J. Trizzino, Executive Vice President, will participate in a fireside chat at Devex @ UNGA 76 on September 21, 2021, at 8:50 a.m. The discussion will focus on the status of Novavax' COVID-19 vaccine candidate, NVX-CoV2373, and initiatives for global vaccine access. The event runs from September 21-23 and will be livestreamed. Novavax is known for its innovative vaccine solutions aimed at serious infectious diseases.
Novavax (Nasdaq: NVAX) announced its involvement in the Phase 2 Com-COV3 clinical trial led by the University of Oxford, aimed at evaluating mixed COVID-19 vaccine schedules in adolescents aged 12-16. The trial will involve at least 360 participants receiving initial doses of authorized vaccines followed by a second dose of either the same or a different vaccine, including NVX-CoV2373. Results are anticipated within months, contributing to flexible vaccination strategies.
Novavax, a biotechnology company, announced participation in two investor conferences. The discussions will center around its recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373. The first event is the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, featuring a fireside chat and a panel on pandemic planning. The second is the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, 2021. Replays of the sessions will be available on Novavax's events page.
Novavax, Inc. (Nasdaq: NVAX) has enrolled the first participants in a Phase 1/2 study assessing the safety and immunogenicity of a combined vaccine for COVID-19 and seasonal influenza. This innovative COVID-NanoFlu Combination Vaccine utilizes Novavax' recombinant protein-based NVX-CoV2373 and NanoFlu™ candidates, enhanced by the Matrix-M™ adjuvant. The trial, set to involve 640 healthy adults aged 50 to 70, will take place across Australia, with results anticipated in the first half of 2022.
Novavax, a biotechnology company focused on next-generation vaccines, announced its participation in Citi's 16th Annual BioPharma Virtual Conference on September 9, 2021. The event will feature a fireside chat discussing Novavax' COVID-19 vaccine candidate, NVX-CoV2373. Key participants from Novavax, including Dr. Gregory M. Glenn and John J. Trizzino, will represent the company. A replay of the session will be available on Novavax's website for 90 days following the event.
The company continues its late-stage trials for NVX-CoV2373 and its influenza vaccine, NanoFlu.